FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review February 28, 2017October 19, 2019 by / Share This.....LinkedinTwitterFacebookGoogleEmailDownload PDF Related News: FDA accepts supplemental Biologics License…FDA accepts application for Roche’s Port Delivery…FDA accepts application for Roche’s faricimab for…US FDA grants Priority Review to Roche’s Tecentriq…Roche’s Evrysdi (risdiplam) granted FDA priority…Roche’s Evrysdi (risdiplam) granted FDA priority…Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)